Evidence map›Paper›PMID 33851133›Full record

ArticleInternational journal of pharmaceutics: X2021

Rafael D Bachmaier, Marius Monschke, Thilo Faber, Anna K Krome, Yann Pellequer, Edmont Stoyanov, Alf Lamprecht, Karl G Wagner

Open access · goldAbstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Rafael D BachmaierDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.
Marius MonschkeDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.
Thilo FaberDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.
Anna K KromeDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.
Yann PellequerUFR Santé, Laboratoire de Pharmacie Galénique, 19, rue Ambroise Paré, 25000 Besancon, France.
Edmont StoyanovNisso Chemical Europe GmbH, Berliner Allee 42, 40212 Düsseldorf, Germany.
Alf LamprechtDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.
Karl G WagnerDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.
University of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Using polymers as additives to formulate ternary amorphous solid dispersions (ASDs) has successfully been established to increase the bioavailability of poorly soluble drugs, when one polymer is not able to provide both, stabilizing the drug in the matrix and the supersaturated solution. Therefore, we investigated the influence of low-viscosity hydroxypropyl cellulose (HPC) polymers as an additive in HPMC based ternary ASD formulations made by hot-melt extrusion (HME) on the bioavailability of itraconazole (ITZ). The partitioning potential of the different HPC grades was screened in biphasic supersaturation assays. Solid-state analytics were performed using differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD). The addition of HPCs, especially HPC-UL, resulted in a superior partitioned amount of ITZ in biphasic supersaturation assays. Moreover, the approach in using HPCs as an additive in HPMC based ASDs led to an increase in partitioned ITZ compared to Sporanox® in biorelevant biphasic dissolution studies. The results from the biphasic dissolution experiments correlated well with the

Indexed as

AcN, acetonitrileAmorphous solid dispersionAPI, active pharmaceutical ingredientASD, amorphous solid dispersionAUC, area under the curveBCS, biopharmaceutical classification systemBiphasic dissolutionDMSO, dimethyl sulfoxideDSC, differential scanning calorimetryFaSSIF, fasted state simulated intestinal fluidGI, gastrointestinalHME, hot-melt extrusionHot-melt extrusionHPCHPC, hydroxypropyl celluloseHPMCHPMC, hydroxypropyl methyl celluloseITZ, itraconazoleKTZ, ketoconazoleNCE, new chemical entityOH-ITZ, hydroxy-itraconazolePM, physical mixtureSD, spray-dryingTG, glass transition temperatureXRPD, x-ray powder diffraction

Identifiers

PMID33851133
PMCPMC8024662
OpenAlexW3153685666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.